Advancements in Targeted Therapy for Untreatable Glioblastoma

Researchers in Massachusetts are testing an experimental therapy called CAN-3110, which uses a genetically modified herpes simplex virus to provoke an immune response against brain cancer cells. The treatment, injected into the tumor, aims to activate the patient's own immune cells to fight off the cancer. Initial results from a Phase I study showed that even patients with existing antibodies to herpes experienced an enhanced immune response. Further studies are needed to determine the effectiveness of CAN-3110, especially in patients without existing herpes antibodies.